Young Cancer Survivors Have Increased Risk for HPV-Linked Subsequent Cancer

2023-05-19
临床结果
FRIDAY, May 19, 2023 -- Adolescent and young adult (AYA) cancer survivors have an increased risk for human papillomavirus (HPV)-associated subsequent malignant neoplasms (SMNs), especially oropharyngeal-SMNs, according to a study published in the May issue of Cancer Epidemiology, Biomarkers & Prevention.
Judy Y. Ou, Ph.D., M.P.H., from the Huntsman Cancer InstituteCancer Institute at the University of Utah in Salt Lake City, and colleagues identified demographic and clinical risk factors for HPV-associated SMNs (HPV-SMN) among AYA cancer survivors in the Surveillance, Epidemiology, and End Results-9 registries diagnosed from 1976 to 2015. Participants started follow-up two months after their original diagnosis.
The researchers found that 1,369 of the 374,408 survivors had an HPV-SMN, which occurred an average of five years after first cancer. AYA survivors had a significantly increased risk for any HPV-SMN and for oropharyngeal-SMNs (standardized incidence ratios [SIR], 1.70 and 2.17, respectively); the risk for cervical-SMN was lower in survivors overall (SIR, 0.85), but was increased in Hispanic AYA survivors (SIR, 1.46). Compared with the general population, AYAs first diagnosed with Kaposi sarcoma, leukemia, and Hodgkin and non-Hodgkin lymphoma had increased risks for HPV-SMN. In age-period-cohort models, oropharyngeal-SMN incidence decreased over time. Among survivors with first HPV-related cancers, but not those whose first cancers were not HPV-related, chemotherapy and radiotherapy were associated with any HPV-SMN.
"HPV-SMNs are preventable through screenings and vaccination. Recommending preventative care from diagnosis onwards among AYA survivors is of great importance," the authors write.
One author disclosed financial ties to the pharmaceutical industry.
Abstract/Full Text (subscription or payment may be required)
Posted May 2023
更多内容,请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点,如有版权侵扰或错误之处,请及时联系我们,我们会在24小时内配合处理。
靶点
-
药物
-
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台,助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台,以API或者数据包形式对外开放,助您更加充分利用智慧芽新药情报信息。